.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01C_PlantAlkaloidsAndOtherNaturalProducts.L01CB01_Etoposide.Etoposide_1 .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01C_PlantAlkaloidsAndOtherNaturalProducts.L01CB01_Etoposide.Etoposide_1| name: | Etoposide_1 |
| ATC code: | L01CB01_1 | route: | oral |
| n-compartments | 2 |
Etoposide is a topoisomerase II inhibitor used as an antineoplastic agent for the treatment of various malignancies including small-cell lung cancer, testicular cancer, lymphoma, and leukemia. It is commonly administered intravenously or orally and is still approved and widely used in cancer chemotherapy.
Pharmacokinetics reported after oral administration in adult patients with cancer.
Toffoli, G, et al., & Boiocchi, M (2001). Population pharmacokinetics and pharmacodynamics of oral etoposide. British journal of clinical pharmacology 52(5) 511–519. DOI:10.1046/j.0306-5251.2001.01468.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/11736859
Nguyen, L, et al., & Canal, P (1998). Population pharmacokinetics of total and unbound etoposide. Cancer chemotherapy and pharmacology 41(2) 125–132. DOI:10.1007/s002800050718 PUBMED:https://pubmed.ncbi.nlm.nih.gov/9443625
Toffoli, G, et al., & Boiocchi, M (2004). Pharmacokinetic optimisation of treatment with oral etoposide. Clinical pharmacokinetics 43(7) 441–466. DOI:10.2165/00003088-200443070-00002 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15139794